![]() ![]() □ Visit atai Life Sciences’ website to learn more. IntelGenX (Partnered for Sublingual Drug Delivery Technology).PsyProtix (Precision Psychiatry Program).InnarisBio (Sol-gel Drug Delivery Program).Introspect (Digital Therapeutics Program).Note: only one lead candidate for each program is listed above. Viridia Life Sciences (VLS-01/DMT – TRD Program).Neuronasal (NN-101/N-Acetylcysteine – mTBI Program).Revixia Life Sciences (RLS-01/Salvinorin A – TRD Program).EmpathBio (EMP-01/MDMA Derivative – PTSD Program).Kures (KUR-101/Deuterated Mitragynine – OUD Program).GABA Therapeutics (GRX-917/Deuterated Etifoxine – GAD Program).DemeRx IB (DMT-1002/Ibogaine – OUD Program).Recognify Life Sciences (RL-007 – CIAS Program).Perception Neuroscience (PCN-101/R-Ketamine – TRD Program).The company is currently supporting several pre-clinical, Phase I, and Phase II trials for indications that include treatment-resistant depression (TRD), generalized anxiety disorder (GAD), mild-traumatic brain injury (mTBI), opioid use disorder (OUD), and post-traumatic stress disorder (PTSD). atai continues to finance and expand its network of pharmaceutical and ‘enabling technology’ development programs. The company’s NASDAQ IPO generated over USD $225 million in proceeds, adding to atai’s already sizable cash reserves. Compounds include classical psychedelic drugs, novel derivatives, and repurposed drugs with prior clinical evidence.Ītai went public in June of 2021. atai then acquires varying degrees of interest in development programs and provides financial and advisory support to spur their growth.Ĭompanies under atai are developing both psychedelic and non-psychedelic drug candidates targeting a wide array of psychiatric treatment indications. The company first works to identify promising technologies and drug treatment programs. atai Life Sciences also owns a significant stake in Compass Pathways, after investing in their Series A round.Ītai presents one of the most unique platform business models in the sector. With tentacles in Berlin, New York and Amsterdam, atai has raised large amounts of backing to finance research and development of new psychiatric medicines and related technologies. Atai is a global biotechnology ‘company builder’, seeking to acquire and develop mental health treatments. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |